Loading
A phase 2 trial of Regorafenib in advanced solid tumours, run by Bayer, active and no longer recruiting.
A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies is a phase 2 interventional study registered as NCT06246643 by Bayer, with 13 participants enrolled, started 2024-01-24 and due to reach its primary completion in 2028-04-27. Interventions recorded: Regorafenib (Stivarga, BAY73-4506).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bayer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bayer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bayer, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Bayer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Anti-angiogenic therapy, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Anti-angiogenic therapy, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/